# A Study of Lurasidone HCl in Subjects With Schizophrenia

> **NCT03393026** · PHASE4 · COMPLETED · sponsor: **Standard Chem. & Pharm. Co., Ltd.** · enrollment: 54 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Lurasidone

## Key facts

- **NCT ID:** NCT03393026
- **Lead sponsor:** Standard Chem. & Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-03
- **Primary completion:** 2019-09-17
- **Final completion:** 2019-09-17
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03393026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03393026, "A Study of Lurasidone HCl in Subjects With Schizophrenia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03393026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*